| |
Group 1
|
Group 2
|
Group 3
|
Group 4
|
|---|
|
No. of Subjects
|
6
|
9
|
11
|
11
|
|
(female)
|
(3)
|
(5)
|
(6)
|
(7)
|
|
Age (range)
|
22–46
|
18–54
|
19–58
|
22–64
|
|
No. of subjects withdrawn
|
1
|
1
|
1
|
2
|
|
Echium Oil Dose (g)
|
14
|
7
|
4
|
2
|
|
No. of daily capsules
|
14
|
7
|
4
|
2
|
|
ALA (g)
|
4.02
|
2.01
|
1.15
|
0.57
|
|
SDA (g)
|
1.75
|
0.875
|
0.5
|
0.25
|
|
GLA (g)
|
1.54
|
0.77
|
0.44
|
0.22
|
|
Borage Oil Dose (g)
|
0
|
3.9
|
5.2
|
5.2
|
|
No. of daily capsules
|
0
|
3
|
4
|
4
|
|
ALA (g)
|
<0.01
|
<0.01
|
<0.01
|
<0.01
|
|
SDA (g)
|
0
|
0
|
0
|
0
|
|
GLA (g)
|
0
|
0.9
|
1.2
|
1.2
|
|
Total
| | | | |
|
No. of daily capsules
|
14
|
10
|
8
|
6
|
|
ALA (g)
|
4.02
|
2.01
|
1.15
|
0.57
|
|
SDA (g)
|
1.75
|
0.875
|
0.5
|
0.25
|
|
GLA (g)
|
1.54
|
1.67
|
1.64
|
1.44
|
- The number of daily capsules, containing 1 g (EO) or 1.3 g (BO) oil per capsule, and the amount of ALA, SDA and GLA provided by the encapsulated echium and borage oils is shown for each dosing group. Recruitment into Group 1 was stopped after the interim analyses showed that the highest dose of EO was not required to prevent elevations of AA levels in circulating plasma.
